Given a paragraph and a claim, classify it this way: If the claim contradicts the evidence present in the paragraph, classify the claim as '0'. If the claim has multiple supporting *AND* contradicting evidences, classify the claim as '1'. If the claim has supporting evidence and the paragraph is in overall favor of the claim, then classify the claim as '2'.

Example Input: Paragraph: US-Patent 8835624 is for the H1N1 virus. The patent with this number was for a strand of DNA that binds to the H1N1 virus, not the virus itself. US patent number 20120251502 is for Ebola. This application number was for a strain of the Ebola virus but the application has now been abandoned. The virus was not created by those who filed the patent. US patent number CA2741523 is for swine flu. This is the application number for a patent for the Ebola virus made to the Canadian Intellectual Property Office. This patent has not been granted, and doesn't mean the Ebola virus was created by someone. 0070031450 A1 is a US patent for BSE (mad cow disease). There is a patent application number one digit away from this that mentions BSE, but is not a patent for BSE itself. ATTC VR-84 is a patent for Zika virus that comes from the Rockefeller Foundation. This is the name of a certain strain of Zika virus, which was first isolated in the 1940s in a lab funded by the Rockefeller Foundation. This strain was not patented. US patents 7897744 and 8506968 are for SARS. The first number is the US patent number for the SARS virus. The patent application was made by the CDC, but after the outbreak in 2002. The second number is a patent for a SARS vaccine which has now expired. US patent 10130701 is for coronavirus. This number is not a patent for the new Wuhan virus, Covid-19. It's a patent for a weakened version of a virus in the same family as Covid-19, a family which includes the common cold and SARS. Claim 1 of 8 Claim: US patents 7897744 and 8506968 are for SARS.
Example Output: 2

Example Input: Paragraph: A Facebook post from the family of 32-year-old Pete Frates said he is resting comfortably at Massachusetts General Hospital and that "doctors, medicine, prayers and love continue to help him get stronger." After some news outlets erroneously reported Monday that he had died, Frates responded by posting a 45-second video on Twitter showing him lying in a hospital bed while the song "Alive" by Pearl Jam plays in the background. Frates' family said Sunday that he had returned to the hospital and was "battling this beast ALS like a Superhero." He was diagnosed with amyotrophic lateral sclerosis in 2012. The disease weakens muscles and impairs physical functioning. There is no known cure. The ALS Ice Bucket Challenge raised more than $220 million when it took off worldwide on social media in 2014. Frates is a native of Beverly, Massachusetts, and played baseball at Boston College. He played professionally in Germany after graduation and in amateur leagues upon his return to the U.S. He received his diagnosis after getting hit on the wrist by a pitch and noticing it wasn't healing properly. Claim: Man who inspired ice bucket challenge is back in hospital.
Example Output: 2

Example Input: Paragraph: There is no mention of costs in the story. Although pridopidine is an experimental drug, it may have been useful for the reader to know whether pridopidine could be at least a cheaper alternative to tetrabenazine, the only drug currently approved for Huntington's disease. The story did not detail the potential benefits of pridopidine. Specifically, how did the patients improve their motor function? The only number provided was that 70% of patients improved. We need to know how this function was measured and to what degree they improved (it is not clear whether the story was talking about statistical significance or clinical significance). The story notes, "Side effects among patients taking the drug were similar to the placebo group." Dr. Alessandro Di Rocco also agrees with this statement, since the "compound is apparently well tolerated without significant side effects." However, the story could have been more thorough in letting the reader know exactly what those side effects are. The story makes contradictory statements on the study's results. At one point, the article reports, "the drug showed a significant benefit," while further down in the article, Dr. Alessandro Di Rocco is quoted as saying, "the benefit is modest and limited to the motor symptoms of the disease." The story could have expanded on Di Rocco's comment and also could have included some of the study's limitations. For example, the researchers could not prove their primary hypothesis, for which they wrote in The Lancet: "This study did not provide evidence of efficacy." The apparent benefits came from the tertiary endpoint, which merits a more cautious interpretation of the results. There is not any disease mongering, but the article does not provide much background information on Huntington's disease, regarding its epidemiology, risk factors and treatments. However, the story does mention dopamine and its role in movement and coordination. Dr. Alessandro Di Rocco from NYU Langone Medical Center is used as an independent source. The story also adds that the study was funded by European pharmaceuticals company NeuroSearch A/S. The article mentions tetrabenazine the only drug on the market for Huntington's disease and adds that it can "cause serious side effects." The story mentions that study results are from a phase III clinical trial, but it does not clearly comment on the availability of pridopidine, or the class of dopidine drugs in general. The story could have simply said that this drug is investigational and is not available yet. Pridopidine is an experimental drug candidate for Huntington's disease and has been in clinical trials for the past several years. The same quotation in the news release is used in the HealthDay story, suggesting that the article was somewhat based off the news release. However, there is some evidence of original reporting, with the inclusion of Dr. Alessandro Di Rocco's comments. Claim: New Drug Shows Promise Against Huntington's Disease
Example Output:
1